Myeloid Therapeutics announced a rebrand to Create Medicines and unveiled a strategic expansion beyond in‑vivo myeloid programming to include T‑cell and NK‑cell programming using its mRNA‑LNP platform. CEO Daniel Getts said the company will pursue directly delivered in‑vivo CAR therapeutics aimed at making scalable, redosable off‑the‑shelf immunotherapies for solid tumors and immune disorders. Create Medicines framed the evolution as leveraging earlier proof points in myeloid reprogramming to broaden therapeutic modalities and validated targets, including HER2, TROP2 and GPC3. The company claims its approach can avoid complex ex‑vivo manufacturing by programming immune cells inside patients, potentially simplifying treatment logistics. The rebrand and strategy shift highlight growing industry interest in directly programmed, in‑vivo cell therapies and the race to translate mRNA‑LNP delivery beyond vaccines into durable oncology and immune modulation therapies.